Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Heather L Gelhorn, Beatrice Osumili, Katelyn Brown, Melissa M Ross, Andrea Schulz, Gabriela Fernandez & Kristina S Boye. (2023) The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes. Patient Preference and Adherence 17, pages 793-805.
Read now
Read now
Simone Rivolo, Jane Loftus, Balazs Peter, Marion Fahey & Thitima Kongnakorn. (2023) Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland. Journal of Medical Economics 26:1, pages 963-972.
Read now
Read now
William Valentine, Kirsi Norrbacka & Kristina Secnik Boye. (2022) Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes. Patient Related Outcome Measures 13, pages 97-111.
Read now
Read now
Vivian T Thieu, Susan Robinson, Tessa Kennedy-Martin, Kristina S Boye & Luis-Emilio Garcia-Perez. (2019) Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes. Patient Preference and Adherence 13, pages 561-576.
Read now
Read now
Kristina S. Boye, Louis S. Matza, Katie D. Stewart, Jessica Jordan, Giovanni Biricolti, Silvia Del Santo, Magaly Perez-Nieves, Marco O. Federici, Raffaella Gentilella, Serena Losi & Kirsi Norrbacka. (2019) Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. Journal of Medical Economics 22:8, pages 806-813.
Read now
Read now
Louis S Matza, Kristina S Boye, Jessica B Jordan, Kirsi Norrbacka, Raffaella Gentilella, Amara R Tiebout, Chantelle Browne, Marco Orsini Federici, Giovanni Biricolti & Katie D Stewart. (2018) Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Preference and Adherence 12, pages 971-979.
Read now
Read now
Heather L Gelhorn, Elizabeth D Bacci, Jiat Ling Poon, Kristina S Boye, Shuichi Suzuki & Steven M Babineaux. (2016) Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan. Patient Preference and Adherence 10, pages 1337-1348.
Read now
Read now
Katie D Stewart, Joseph A Johnston, Louis S Matza, Sarah E Curtis, Henry A Havel, Stephanie A Sweetana & Heather L Gelhorn. (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence 10, pages 1385-1399.
Read now
Read now
A. Brett Hauber, Hiep Nguyen, Joshua Posner, Iftekhar Kalsekar & James Ruggles. (2016) A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Current Medical Research and Opinion 32:2, pages 251-262.
Read now
Read now
Heather L Gelhorn, Jiat-Ling Poon, Evan W Davies, Rosirene Paczkowski, Sarah E Curtis & Kristina S Boye. (2015) Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK. Patient Preference and Adherence 9, pages 1611-1622.
Read now
Read now
Kristina S Boye, Louis S Matza, David H Feeny, Joseph A Johnston, Lee Bowman & Jessica B Jordan. (2014) Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?. Expert Review of Pharmacoeconomics & Outcomes Research 14:3, pages 437-450.
Read now
Read now
Louis S Matza, Ze Cong, Karen Chung, Alison Stopeck, Katia Tonkin, Janet Brown, Ada Braun, Kate Van Brunt & Kelly McDaniel. (2013) Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Preference and Adherence 7, pages 855-865.
Read now
Read now
Won Chan Lee, Yevgeniy Samyshkin, Jakob Langer & James L. Palmer. (2012) Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. Journal of Medical Economics 15:sup2, pages 28-37.
Read now
Read now
Articles from other publishers (37)
Kristina S. Boye, Jessica B. Jordan, Raleigh Malik & Louis S. Matza. (2023) Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States. Diabetes Therapy.
Crossref
Crossref
Jay H. Shubrook, Michael Radin, Sarah N. Ali, Barrie Chubb, Kristina DiPietrantonio, Hannah Collings, Robin Wyn & Martina Smith. (2022) Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment. Advances in Therapy 39:9, pages 4114-4130.
Crossref
Crossref
Akram Ahmad, Muhammad Umair Khan & Parisa Aslani. (2022) Patient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment. Journal of Diabetes & Metabolic Disorders 21:1, pages 229-240.
Crossref
Crossref
José L. Górriz, Irene Romera, Amelia Cobo, Phillipe D. O’Brien & Juan F. Merino-Torres. (2022) Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Therapy 13:3, pages 389-421.
Crossref
Crossref
Yuankai Huang, Qixiang Huang, Ailin Xu, Mengqing Lu & Xiaoyu Xi. (2022) Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment. Frontiers in Public Health 9.
Crossref
Crossref
Kristina S. Boye, Jessica B. Jordan, Raleigh E. Malik, Brooke M. Currie & Louis S. Matza. (2021) Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments. Diabetes Therapy 12:9, pages 2387-2403.
Crossref
Crossref
Louis S. Matza, Katelyn N. Cutts, Katie D. Stewart, Kirsi Norrbacka, Luis-Emilio García-Pérez & Kristina S. Boye. (2021) Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research 30:7, pages 2033-2043.
Crossref
Crossref
Axel C. Mühlbacher, Andrew Sadler & Christin Juhnke. (2021) Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment. The European Journal of Health Economics 22:3, pages 425-443.
Crossref
Crossref
Ataru Igarashi, Brian Bekker Hansen, Jakob Langer, Francesca Tavella, Hannah Collings, Neil Davies & Robin Wyn. (2020) Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment. Advances in Therapy 38:1, pages 721-738.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas & Luis‐Emilio García‐Pérez. (2019) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism 22:3, pages 355-364.
Crossref
Crossref
Mahdi Toroski, Abbas Kebriaeezadeh, Alireza Esteghamati, Ali Kazemi Karyani, Hadi Abbasian & Shekoufeh Nikfar. (2019) Patient and physician preferences for type 2 diabetes medications: a systematic review. Journal of Diabetes & Metabolic Disorders 18:2, pages 643-656.
Crossref
Crossref
Johan Jendle, Andreas L. Birkenfeld, William H. Polonsky, Robert Silver, Kari Uusinarkaus, Thomas Hansen, Jonas Håkan‐Bloch, Sayeh Tadayon & Melanie J. Davies. (2019) Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials. Diabetes, Obesity and Metabolism 21:10, pages 2315-2326.
Crossref
Crossref
Christin Juhnke & Axel C. Mühlbacher. (2019) Patientenpräferenzen: Wünsche von Betroffenen mit Diabetes mellitusPatient preferences: what do diabetes patients want?. Der Diabetologe 15:6, pages 534-541.
Crossref
Crossref
Anne Brooks, Jakob Langer, Tommi Tervonen, Mads Peter Hemmingsen, Kosei Eguchi & Elizabeth Dansie Bacci. (2019) Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment. Diabetes Therapy 10:2, pages 735-749.
Crossref
Crossref
Michael A. Nauck, John B. Buse, Johannes F. E. Mann, Stuart Pocock, Heidrun Bosch-Traberg, Helle Frimer-Larsen, Qing Ye & Alastair Gray. (2019) Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes, Obesity and Metabolism 21:3, pages 525-532.
Crossref
Crossref
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta & Jesús Reviriego. (2018) A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Therapy 10:1, pages 5-19.
Crossref
Crossref
Mark Oremus, Anis Sharafoddini, Gian Paolo Morgano, Xuejing Jin & Feng Xie. (2018) A Computer-Assisted Personal Interview App in Research Electronic Data Capture for Administering Time Trade-off Surveys (REDCap): Development and Pretest. JMIR Formative Research 2:1, pages e3.
Crossref
Crossref
Sten Madsbad & Jens J. Holst. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
571
615
.
Sten Madsbad & Jens J. Holst. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
45
.
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Evan W. Davies & Rosirene Paczkowski. (2017) Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Services Research 17:1.
Crossref
Crossref
Anna Rydén, Stephanie Chen, Emuella Flood, Beverly Romero & Susan Grandy. (2017) Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus. The Patient - Patient-Centered Outcomes Research 10:4, pages 475-487.
Crossref
Crossref
Lill-Brith von Arx, F. Reed Johnson, Morten Raun Mørkbak & Trine Kjær. (2017) Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients’ Benefit-Risk Tradeoff Preferences. Value in Health 20:4, pages 670-678.
Crossref
Crossref
Richard De Abreu Lourenco, Marion Haas, Jane Hall & Rosalie Viney. (2016) Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence. PharmacoEconomics 35:3, pages 347-362.
Crossref
Crossref
Axel Mühlbacher & Susanne Bethge. (2015) What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. The European Journal of Health Economics 17:9, pages 1125-1140.
Crossref
Crossref
Ellen M. Janssen, Jodi B. Segal & John F. P. Bridges. (2016) A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. The Patient - Patient-Centered Outcomes Research 9:5, pages 465-479.
Crossref
Crossref
Sten Madsbad. (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism 18:4, pages 317-332.
Crossref
Crossref
Sieta T. de Vries, Folgerdiena M. de Vries, Thijs Dekker, Flora M. Haaijer-Ruskamp, Dick de Zeeuw, Adelita V. Ranchor & Petra Denig. (2015) The Role of Patients’ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. PLOS ONE 10:10, pages e0139755.
Crossref
Crossref
Peter G. M. Mol, Arna H. Arnardottir, Sabine M. J. Straus, Pieter A. de Graeff, Flora M. Haaijer-Ruskamp, Elise H. Quik, Paul F. M. Krabbe & Petra Denig. (2015) Understanding drug preferences, different perspectives. British Journal of Clinical Pharmacology 79:6, pages 978-987.
Crossref
Crossref
Axel C. Mühlbacher & A. Kaczynski. (2015) Patientenpräferenzen in der medikamentösen Therapie von Diabetes Mellitus Typ 2Patients’ preferences in the medicamentous treatment of diabetes mellitus type 2. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 58:4-5, pages 452-466.
Crossref
Crossref
Lill-Brith von Arx & Trine Kjær. (2014) The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research. The Patient - Patient-Centered Outcomes Research 7:3, pages 283-300.
Crossref
Crossref
Tanjala S. Purnell, Susan Joy, Emily Little, John F.P. Bridges & Nisa Maruthur. (2014) Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review. Diabetes Care 37:7, pages 2055-2062.
Crossref
Crossref
Susan M. Joy, Emily Little, Nisa M. Maruthur, Tanjala S. Purnell & John F. P. Bridges. (2013) Patient Preferences for the Treatment of Type 2 Diabetes: A Scoping Review. PharmacoEconomics 31:10, pages 877-892.
Crossref
Crossref
H. L. Gelhorn, S. M. Stringer, A. Brooks, C. Thompson, B. U. Monz, K. S. Boye, T. Hach, S. S. Lund & R. Palencia. (2013) Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism 15:9, pages 802-809.
Crossref
Crossref
Victoria K. Brennan & Simon Dixon. (2013) Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies. PharmacoEconomics 31:8, pages 677-691.
Crossref
Crossref
Sue D. Pedersen. (2013) Impact of Newer Medications for Type 2 Diabetes on Body Weight. Current Obesity Reports 2:2, pages 134-141.
Crossref
Crossref
M. Davies & J. Speight. (2012) Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 14:10, pages 882-892.
Crossref
Crossref
Daisuke YabeYutaka Seino. (2011) Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference. Clinical Medicine Insights: Endocrinology and Diabetes 4, pages CMED.S5976.
Crossref
Crossref